<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03026088</url>
  </required_header>
  <id_info>
    <org_study_id>MS200006-0039</org_study_id>
    <nct_id>NCT03026088</nct_id>
  </id_info>
  <brief_title>Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Subjects</brief_title>
  <acronym>Biso-CHF</acronym>
  <official_title>A Single-arm, Interventional, Multi-center, Pilot Study to Evaluate the Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Patients With NYHA Class II - IV (Biso-CHF Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono Co., Ltd., China</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open label, interventional, multi-center, phase IV pilot study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Resting Heart Rate under 2.5 mg of Bisoprolol at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Resting heart rate measurement will be taken at sitting position for a continuous record of 3 minutes. Heartbeats in each minute will be calculated and averaged to obtain the resting heart rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Resting Heart Rate under 5 mg of Bisoprolol at Week 14</measure>
    <time_frame>Baseline and Week 14</time_frame>
    <description>Resting heart rate measurement will be taken at sitting position for a continuous record of 3 minutes. Heartbeats in each minute will be calculated and averaged to obtain the resting heart rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Resting Heart Rate under 10 mg of Bisoprolol at Week 26</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>Resting heart rate measurement will be taken at sitting position for a continuous record of 3 minutes. Heartbeats in each minute will be calculated and averaged to obtain the resting heart rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Resting Heart Rate under 1.5 mg, 3.75 mg and 7.5 mg of Bisoprolol at Week 3, 10, and 18, respectively</measure>
    <time_frame>Baseline, Week 3, 10, and 18</time_frame>
    <description>Resting heart rate measurement will be taken at sitting position for a continuous record of 3 minutes. Heartbeats in each minute will be calculated and averaged to obtain the resting heart rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction (LVEF) at Baseline, Week 14 and Week 26</measure>
    <time_frame>Baseline, Week 14 and Week 26</time_frame>
    <description>Echocardiography will be performed to measure LVEF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricle end-diastolic dimension (LVEDD) at Baseline, Week 14 and Week 26</measure>
    <time_frame>Baseline, Week 14 and Week 26</time_frame>
    <description>Echocardiography will be performed to measure LVEDD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end-systolic dimension (LVESD) at Baseline, Week 14 and Week 26</measure>
    <time_frame>Baseline, Week 14 and Week 26</time_frame>
    <description>Echocardiography will be performed to measure LVESD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter-ventricular septal thickness (IVST) at Baseline, Week 14 and Week 26</measure>
    <time_frame>Baseline, Week 14 and Week 26</time_frame>
    <description>Echocardiography will be performed to measure IVST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early (E) to Late (A) (E/A ratio) at Baseline, Week 14 and Week 26</measure>
    <time_frame>Baseline, Week 14 and Week 26</time_frame>
    <description>Echocardiography will be performed to measure E/A ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic blood pressure</measure>
    <time_frame>Screening (Week -2), Baseline, Weeks 3, 6, 10, 14,18 and 26</time_frame>
    <description>Blood pressure measurement will be taken at sitting position, with the elbow at the same level with the heart. Diastolic and systolic blood pressure will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms and New York Heart Association (NYHA) classification at all visits (Visit 1 to 8)</measure>
    <time_frame>Screening (Week -2), Baseline, Weeks 3, 6, 10, 14,18 and 26</time_frame>
    <description>The NYHA classification assesses the severity of symptoms of heart failure and is comprised of 4 stages. Here NYHA class of II - IV will be assessed. NYHA II: Slight limitation of physical activity, comfortable at rest, but ordinary physical activity results in undue breathlessness, fatigue or palpitation. NYHA III: Marked limitation of physical activity, comfortable at rest, but less than ordinary activity causes undue breathlessness, fatigue or palpitation. NYHA IV: Unable to carry on any physical activity without discomfort, symptoms at rest can be present. If any physical activity is undertaken, discomfort increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects Having Resting heart rate less than 70 beats per minute (bpm) and more than 55 bpm at all visits (Visit 1 to 8)</measure>
    <time_frame>Screening (Week -2), Baseline, Weeks 3, 6, 10, 14,18 and 26</time_frame>
    <description>Resting heart rate measurement will be taken at sitting position for a continuous record of 3 minutes. Heartbeats in each minute will be calculated and averaged to obtain the resting heart rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life based on the Minnesota Living with Heart Failure (MLHF) at baseline and end of treatment</measure>
    <time_frame>Baseline, end of treatment (Week 26)</time_frame>
    <description>MLHF questionnaire has 21 items. Questions assess the impact of frequent physical symptoms of heart failure and the effects of heart failure on physical and social functions. Each question had a possible score of 0 (best) to 5 (worst), for a total of 0 to 105. The higher the summed score, the worse is the impact of heart failure on a subject's quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life based on the Medical Outcomes Study item short from health survey (SF-36) at baseline and end of treatment</measure>
    <time_frame>Baseline, end of treatment (Week 26)</time_frame>
    <description>The SF-36 assesses 8 health status domains (that is, physical functioning, role physical functioning, role emotional functioning, mental health, vitality, social functioning, bodily pain, and general health). Scale scores are obtained by summing the items together within a domain, dividing this outcome by the range of scores and then transforming the raw scores to a scale from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk test at Baseline and end of treatment</measure>
    <time_frame>Baseline and End of treatment (Week 26)</time_frame>
    <description>6-min walk test: is a practical simple test that requires a 100-ft hallway but no exercise equipment or advanced training for technicians. Walking is an activity performed daily by all but the most severely impaired subjects. This test measures the distance that a subject can quickly walk on a flat, hard surface in a period of 6 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal Pro-B-type Natriuretic Peptide (NT Pro-BNP) at Baseline and End of treatment</measure>
    <time_frame>Baseline and End of treatment (Week 26)</time_frame>
    <description>Routine blood tests will be performed to measure NT Pro-BNP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean 24 hour, daytime and night time heart rate at Baseline, Weeks 6, 14 and end of treatment (Week 26)</measure>
    <time_frame>Baseline, week 6, 14 and end of treatment (Week 26)</time_frame>
    <description>Holter monitor will be used to measure heart rate (24 hour, day time, night time).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with arrhythmia at baseline, week 6, 14 and end of treatment (Week 26)</measure>
    <time_frame>Baseline, week 6, 14 and end of treatment (Week 26)</time_frame>
    <description>Holter monitor will be used to diagnose arrhythmia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with 24 hour heart rate with more than 70 beats per minute (bpm) and less than 55 bpm at baseline, week 6, 14 and end of treatment (Week 26)</measure>
    <time_frame>Baseline, week 6, 14 and end of treatment (Week 26)</time_frame>
    <description>Holter monitor will be used to measure heart rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Compliance assessed by Medication possession ratio (MPR) at the end of study</measure>
    <time_frame>End of study (Week 26)</time_frame>
    <description>MPR is used to assess the medicine compliance. MPR is defined as the actual drug number taken by the patients divided by the drug number should be taken by the patients according to the protocol. MPR between 80%-100% is defined as good compliance. Medication rate of &lt;80% or &gt;100% is defined as insufficient compliance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with All cause mortality, cardiac death, or re-admission due to heart failure at the end of study</measure>
    <time_frame>End of study (Week 26)</time_frame>
    <description>Number of Subjects with All-cause mortality, cardiac death, or re-admission due to heart failure at the end of study will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Bisoprolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol</intervention_name>
    <description>Subjects will receive Bisoprolol at a dose of 1.25 milligram (mg) up to Weeks 3, and then it will be up-titrated to 2.5 mg up to Week 6 , 3.75 mg up to Week 10, 5 mg up to Week 14, 7.5 mg up to Week 18, and 10 mg up to Week 26.</description>
    <arm_group_label>Bisoprolol</arm_group_label>
    <other_name>Brand name: Concor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 year, male or female.

          -  Chronic Heart failure subjects with medical history of cardiac disease or other
             related cardiovascular disease.

          -  Left ventricular ejection fraction (LVEF) less than or equal to (=&lt;) 40 percent (%).

          -  New York Heart Association (NYHA) class of II - IV

          -  NYHA II ： Slight limitation of physical activity. Comfortable at rest, but ordinary
             physical activity results in undue breathlessness, fatigue or palpitation.

          -  NYHA III：Marked limitation of physical activity. Comfortable at rest, but less than
             ordinary activity causes undue breathlessness, fatigue or palpitation.

          -  NYHA IV：Unable to carry on any physical activity without discomfort. Symptoms at rest
             can be present. If any physical activity is undertaken, discomfort increased.

          -  Signed Informed Consent Form (ICF).

        Exclusion Criteria:

          -  Acute coronary syndrome (ACS) within 3 months.

          -  Under beta-blocker treatment for the last 2 weeks.

          -  Under other medicine treatment which may affect heart rate, like Non-dihydropyridine
             calcium channel blockers (NDHP-CCBs) or ivabradine for the last 2 weeks; Under Digoxin
             treatment [more than (&gt;) 0.125 milligram (mg)].

          -  Uncontrolled Diabetes [hemoglobin A1c, (HbA1c) &gt;7.5%].

          -  Severe or uncontrolled hypertension [resting Systolic Blood Pressure (SBP) &gt;180
             millimeters of mercury (mmHg), or resting Diastolic Blood Pressure (DBP) &gt;110mmHg at
             screening period].

          -  Severe hypotension [resting SBP less than (&lt;) 90mmHg, or resting DBP&lt;50mmHg].

          -  Resting heart rate &lt;60 beat per minute (bpm).

          -  Any contradiction to Bisoprolol according to label, including:

          -  Acute heart failure or during episodes of heart failure decompensation requiring
             intravenous inotropic therapy.

          -  Cardiogenic shock.

          -  Atrioventricular block of second or third degree (without a pacemaker).

          -  Sick sinus syndrome.

          -  Sinoatrial block.

          -  Slowed heart rate, causing symptoms (symptomatic bradycardia),

          -  Decreased blood pressure, causing symptoms (symptomatic hypotension),

          -  Severe bronchial asthma or severe chronic obstructive pulmonary disease.

          -  Sever forms of peripheral arterial occlusive disease and Raynaud's syndrome.

          -  Untreated phaeochromocytoma.

          -  Metabolic acidosis.

          -  Hypersensitivity to bisoprolol or to any of the excipients.

          -  Severe Arrhythmia including atrial fibrillation, atrial flutter, ventricular
             fibrillation, ventricular flutter or ventricular tachycardia.

          -  Significant valvular heart disease, congenital heart disease, pulmonary heart disease
             or perinatal heart disease.

          -  Acute pulmonary edema.

          -  Severe hepatic dysfunction, defined as:

          -  Serum Alanine Aminotransferase (ALT) &gt; triple the upper limit of the normal range;
             and/or

          -  Serum Aspartate Aminotransferase (AST) &gt; triple the upper limit of the normal value
             range and/or

          -  Severe renal dysfunction, defined as:

          -  Serum creatinine &gt; twice the upper limit of the normal range

          -  Chronic Kidney Disease (glomerular filtration rate &lt;45 Milliliter per minute).

          -  Hyperthyroidism or hypothyroidism.

          -  Severe infectious disease, example (eg) Human Immunodeficiency Virus positive or
             active tuberculosis.

          -  Severe autoimmune disease, e.g. lupus erythematosus, multiple sclerosis.

          -  Severe respiratory, digestive, hematological disease (including Anemia of Hb &lt; 100
             gram per litre) or tumor.

          -  Known to be hypersensitivity to Bisoprolol, or any of the excipient.

          -  Substance or alcohol abuse.

          -  Received heart transplantation or pacemaker implantation; revascularization treatment
             within 3 months; or plan to receive above treatment in 6 months.

          -  Currently undertaking other treatment that may affect the safety and/or efficacy
             evaluation, e.g. beta receptors agonists, et cetera.

          -  No legal ability or legal ability is limited.

          -  Subjects unlikely to cooperate in the study or with inability or unwillingness to give
             informed consent.

          -  Child-bearing period women without effective contraceptive measures, pregnancy and
             lactation.

          -  Participation in another clinical trial within the past 90 days.

          -  Other significant condition that in the Investigator's opinion would exclude the
             subject from the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Serono Co., Ltd., China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merck KGaA Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@merckgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuwai Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Zhang</last_name>
      <phone>+86010-88398263</phone>
      <email>fwzhangjian62@126.com</email>
    </contact>
    <investigator>
      <last_name>Jian Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2017</study_first_submitted>
  <study_first_submitted_qc>January 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2017</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Heart Failure</keyword>
  <keyword>Bisoprolol</keyword>
  <keyword>Heart rate control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bisoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

